Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

INTRODUCTION: The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year. METHODS: Subjects were aged ≥50 years with...

Descripción completa

Detalles Bibliográficos
Autores principales: Landen, Jaren W., Andreasen, Niels, Cronenberger, Carol L., Schwartz, Pamela F., Börjesson-Hanson, Anne, Östlund, Henrik, Sattler, Catherine A., Binneman, Brendon, Bednar, Martin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651442/
https://www.ncbi.nlm.nih.gov/pubmed/29067345
http://dx.doi.org/10.1016/j.trci.2017.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651442/
https://www.ncbi.nlm.nih.gov/pubmed/29067345
http://dx.doi.org/10.1016/j.trci.2017.05.003

Ejemplares similares